Article ; Online: Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.
2023 Volume 40, Issue 10, Page(s) 4117–4126
Abstract: Brain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. ... ...
Abstract | Brain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. Lorlatinib is a brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), which has a high potency against resistance mutations seen with earlier generation ALK TKIs. In 2018, lorlatinib was granted accelerated approval in second- and third-line treatment for use in patients with ALK-positive metastatic NSCLC on the basis of phase 1/2 study results. This initial approval was expanded for first-line treatment of patients with ALK-positive metastatic NSCLC on the basis of the interim analysis of the phase 3 CROWN study showing longer progression-free survival, time to intracranial progression, duration of response, and objective response rate compared with crizotinib. This manuscript is a transcript of our podcast, in which we discuss the clinical significance of controlling the onset of brain metastases, considerations in selecting a first-line therapy option, efficacy and safety observed in patients with and without brain metastases, and rationales for using lorlatinib upfront versus reserving for a later line in therapy. |
---|---|
MeSH term(s) | Humans ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/pathology ; Quality of Life ; Anaplastic Lymphoma Kinase ; Lactams, Macrocyclic/therapeutic use ; Lactams, Macrocyclic/adverse effects ; Protein Kinase Inhibitors ; Brain Neoplasms/drug therapy |
Chemical Substances | lorlatinib (OSP71S83EU) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1) ; Lactams, Macrocyclic ; Protein Kinase Inhibitors |
Language | English |
Publishing date | 2023-08-12 |
Publishing country | United States |
Document type | Clinical Trial, Phase II ; Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 632651-1 |
ISSN | 1865-8652 ; 0741-238X |
ISSN (online) | 1865-8652 |
ISSN | 0741-238X |
DOI | 10.1007/s12325-023-02606-x |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2101: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.